主要职责：保证每月拜访规定数量的目标客户和组织产品学术推广会，配合公司大型学术活动建立完善的客户管理体系，提高客户服务质量及时、准确执行报告系统，及时汇报工作的进展，及时反馈市场信息配合地区经理的协同拜访完成地区经理或者大区经理指派的工作任务积极参与和推进合规项目 ...

Accessibility and accommodation Novartis is committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Careers at Novartis in Slovenia At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

Offene Stellen Mehr als 70.000 Mitarbeitende setzen sich bei Novartis weltweit gemeinsam dafür ein, das Leben von Patient*innen zu verlängern und zu verbessern. Willst du dabei sein? Dann denke mit ...

Modern Slavery Statement 2024 - Australia, Canada, and United Kingdom (PDF 0.3 MB) Our statement under UK, Canadian and Australian legislation on our efforts to address modern slavery. Norwegian ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...

Note: Report Adverse events for Novartis Products only. Alternatively, if you are unable to report the side effect electronically you can email your local Novartis Drug Safety Responsible person. When ...

Product portfolio At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these ...

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...

September 25, 2025 - Bank of America Merrill Lynch Global Healthcare Conference ...

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah ...